Indian chemicals score on CRAMS

Jubiliant Organosys’ announcement that it has clinched deals worth $60m from global life science majors reinforces India’s growing strength in the custom research and manufacturing services (CRAMS) business.

Rising competition and research costs are supporting the CRAMS outsourcing wave and beneficiaries include Shasun Chemicals, Nicholas Piramal, Divis Lab and Dishman Pharma.

A report in the Financial Express estimates that the Indian CRAMs business is growing at 25-30% annually with local companies investing in new facilities to capture a bigger share of the $35bn global CARMS business. And opportunities abound as drugs worth about $85bn are expected to go off patent in the new few years.

Subscribe

Subscribe to our e-mail newsletter to receive updates.

, ,

Leave a Reply